AbbVie competitorsClear all

Astellas Pharma's top competitors include Gilead Sciences, Immunomedics, Sanofi, Amgen, Bristol-Myers Squibb, Abbott, Merck Group, GSK, Novartis, Roche and Johnson & Johnson.
Astellas Pharma
Astellas Pharma
Astellas Pharma is a pharmaceutical company focused on the development of drugs and medical solutions.
Gilead Sciences
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Immunomedics
Immunomedics
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
Sanofi
Sanofi
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Amgen
Amgen
Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with serious and life-threatening diseases.
Abbott
Abbott
Abbott is a healthcare company specializing in diagnostics, medical devices, nutritionals, and branded generic medicines.
Merck Group
Merck Group
Merck Group is a pharmaceutical, chemical, and life sciences company.
GSK
GSK
GSK (GlaxoSmithKline) is a science-led healthcare company.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Roche
Roche
Roche (also known as F. Hoffmann-La Roch) is a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Founding Date
Founding Date
1923
Founding Date
1987
Founding Date
1982
Founding Date
2004
Founding Date
1980
Founding Date
1887
Founding Date
1888
Founding Date
1668
Founding Date
2000
Founding Date
1996
Founding Date
1896
Founding Date
1886
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Tokyo, JP HQ
Macquarie Park, AU
Wien, AT
Vilvoorde, BE
São Paulo, BR
Markham, CA
Beijing, CN
see more
Locations
Foster City, US HQ
Abb, AR
Melbourne, AU
Wien, AT
Machelen, BE
São Paulo, BR
Edmonton, CA
see more
Locations
Morris Plains, US HQ
Rödermark, DE
Locations
Paris, FR HQ
Macquarie Park, AU
Wien, AT
Dhaka, BD
Brussel, BE
Geel, BE
Zaventem, BE
see more
Locations
Thousand Oaks, US HQ
Hydra, DZ
Vicente López, AR
Kew, AU
North Ryde, AU
Wien, AT
Machelen, BE
see more
Locations
New York, US HQ
Braine L'alleud, BE
Watermaal Bosvoorde, BE
Montréal, CA
Pudong Xinqu, CN
Virum, DK
Espoo, FI
see more
Locations
Lake Bluff, US HQ
Tiranë, AL
Buenos Aires, AR
Yerevan, AM
Doncaster, AU
Macquarie Park, AU
Melbourne, AU
see more
Locations
Darmstadt, DE HQ
Hydra, DZ
Csd, AR
Bayswater, AU
Bayswater, AU
Macquarie Park, AU
Wien, AT
see more
Locations
Brentford, GB HQ
Boudouaou, DZ
San Fernando, AR
Abbotsford, AU
Boronia, AU
Ermington, AU
Wien, AT
see more
Locations
Basel, CH HQ
Tirana, AL
Bir Mourad Raïs, DZ
Duc, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
see more
Locations
Basel, CH HQ
Hydra, DZ
Ricardo Rojas, AR
North Ryde, AU
Sydney, AU
Wien, AT
Wien, AT
see more
Locations
New Brunswick, US HQ
Buenos Aires, AR
Chippendale, AU
Wien, AT
Minsk, BY
Beerse, BE
Brussel, BE
see more
Employees
Employees
15,8832% decrease
Employees
11,8007% increase
Employees
3666% increase
Employees
100,4094% decrease
Employees
23,4009% increase
Employees
30,00029% increase
Employees
107,0004% increase
Employees
58,1272% increase
Employees
99,4374% increase
Employees
105,7942% increase
Employees
97,735
Employees
132,2002% decrease
Valuation ($)
Valuation ($)
28.7 b
Valuation ($)
86.3 b
Valuation ($)
20.3 b
Valuation ($)
131.5 b
Valuation ($)
144.4 b
Valuation ($)
144.9 b
Valuation ($)
209.6 b
Valuation ($)
73.7 b
Valuation ($)
95.6 b
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
448.3 b
Twitter followers
Twitter followers
50.4 k
Twitter followers
67.7 k
Twitter followers
605
Twitter followers
141.2 k
Twitter followers
99.7 k
Twitter followers
152.2 k
Twitter followers
107 k
Twitter followers
20.7 k
Twitter followers
223.1 k
Twitter followers
292.8 k
Twitter followers
231.8 k
Twitter followers
231.9 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
25
Number of tweets (last 30 days)
13
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
44
Number of tweets (last 30 days)
102
Number of tweets (last 30 days)
69
Number of tweets (last 30 days)
282
Number of tweets (last 30 days)
100
Number of tweets (last 30 days)
79
Number of tweets (last 30 days)
21
Number of tweets (last 30 days)
51
Number of tweets (last 30 days)
78
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
5.8
Average likes per tweet (last 30 days)
81.2
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
15.3
Average likes per tweet (last 30 days)
10.8
Average likes per tweet (last 30 days)
6.8
Average likes per tweet (last 30 days)
8.3
Average likes per tweet (last 30 days)
4.7
Average likes per tweet (last 30 days)
15.8
Average likes per tweet (last 30 days)
11.5
Average likes per tweet (last 30 days)
9.8
Average likes per tweet (last 30 days)
10.6
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
96%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
98.04%
Percentage of tweets with engagement (last 30 days)
98.55%
Percentage of tweets with engagement (last 30 days)
59.93%
Percentage of tweets with engagement (last 30 days)
89%
Percentage of tweets with engagement (last 30 days)
93.67%
Percentage of tweets with engagement (last 30 days)
66.67%
Percentage of tweets with engagement (last 30 days)
80.39%
Percentage of tweets with engagement (last 30 days)
47.44%
Alexa Website Rank
Alexa Website Rank
270550
Alexa Website Rank
112610
Alexa Website Rank
282560
Alexa Website Rank
123373
Alexa Website Rank
200877
Alexa Website Rank
101235
Alexa Website Rank
42367
Alexa Website Rank
150790
Alexa Website Rank
58088
Alexa Website Rank
88970
Alexa Website Rank
45834
Alexa Website Rank
19571
Employee Rating
Employee Rating
3.1
Employee Rating
3.8
Employee Rating
3.2
Employee Rating
3.3
Employee Rating
4
Employee Rating
4.1
Employee Rating
3.9
Employee Rating
4
Employee Rating
3.8
Employee Rating
4.2
Employee Rating
N/A
Employee Rating
4.2

Financial

Revenue (est.)
Revenue (est.)
¥1.3t (FY, 2020)
Revenue (est.)
$24.7b (FY, 2020)
Revenue (est.)
$295k (FY, 2019)
Revenue (est.)
(€926m) (FY, 2020)
Revenue (est.)
$25.4b (FY, 2020)
Revenue (est.)
$42.5b (FY, 2020)
Revenue (est.)
$34.6b (FY, 2020)
Revenue (est.)
€17.5b (FY, 2020)
Revenue (est.)
£33.8b (FY, 2019)
Revenue (est.)
$48.7b (FY, 2020)
Revenue (est.)
CHF63.8b (FY, 2019)
Revenue (est.)
$82.1b (FY, 2019)
Cost of goods
Cost of goods
¥276.7b (FY, 2020)
Cost of goods
$4.6b (FY, 2020)
Cost of goods
N/A
Cost of goods
€12.2b (FY, 2020)
Cost of goods
$6.2b (FY, 2020)
Cost of goods
$11.8b (FY, 2020)
Cost of goods
$15b (FY, 2020)
Cost of goods
€6.8b (FY, 2020)
Cost of goods
£11.9b (FY, 2019)
Cost of goods
$15.1b (FY, 2020)
Cost of goods
CHF18.4b (FY, 2019)
Cost of goods
$27.6b (FY, 2019)
Gross profit
Gross profit
¥1t (FY, 2020)
Gross profit
$20.1b (FY, 2020)
Gross profit
$295k (FY, 2019)
Gross profit
(€13.1b) (FY, 2020)
Gross profit
$19.3b (FY, 2020)
Gross profit
$30.7b (FY, 2020)
Gross profit
$19.6b (FY, 2020)
Gross profit
€10.7b (FY, 2020)
Gross profit
£21.9b (FY, 2019)
Gross profit
$33.5b (FY, 2020)
Gross profit
CHF45.4b (FY, 2019)
Gross profit
$54.5b (FY, 2019)
Net income
Net income
¥195.4b (FY, 2020)
Net income
$89m (FY, 2020)
Net income
($357.3m) (FY, 2019)
Net income
€12.4b (FY, 2020)
Net income
$7.3b (FY, 2020)
Net income
($9b) (FY, 2020)
Net income
$4.5b (FY, 2020)
Net income
€2b (FY, 2020)
Net income
£5.3b (FY, 2019)
Net income
$8.1b (FY, 2020)
Net income
CHF14.1b (FY, 2019)
Net income
$15.1b (FY, 2019)

Operating

Countries
Countries
N/A
Countries
35 (FY, 2019)
Countries
N/A
Countries
N/A
Countries
100 (FY, 2019)
Countries
N/A
Countries
N/A
Countries
66 (FY, 2020)
Countries
N/A
Countries
N/A
Countries
N/A
Countries
60 (FY, 2018)
Manufacturing Facilities
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
7 (FY, 2019)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
87 (FY, 2016)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
97 (FY, 2019)
Manufacturing Sites
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
92 (FY, 2019)
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
23 (FY, 2019)
Manufacturing Sites
N/A
New Product Launches
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
25 (FY, 2018)
New Product Launches
N/A
New Product Launches
30 (FY, 2016)
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
N/A
Patent Applications (US)
Patent Applications (US)
N/A
Patent Applications (US)
394 (Dec, 2020)
Patent Applications (US)
275 (Sep, 2020)
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patents (US)
Patents (US)
N/A
Patents (US)
650 (Dec, 2020)
Patents (US)
390 (Sep, 2020)
Patents (US)
N/A
Patents (US)
34 (FY, 2019)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2019)
Phase I Trials Products
N/A
Phase I Trials Products
22 (FY, 2019)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
12 (FY, 2019)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products (Immunology)
Phase I Trials Products (Immunology)
1 (Oct, 2020)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
5 (FY, 2019)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
7 (Dec, 2020)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
1 (FY, 2020)
Phase I Trials Products (Oncology)
7 (FY, 2019)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
12 (FY, 2020)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
19 (FY, 2019)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
43 (Dec, 2020)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Other)
Phase I Trials Products (Other)
3 (Oct, 2020)
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
2 (Dec, 2020)
Phase I Trials Products (Other)
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2019)
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2019)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products (Immunology)
Phase II Trials Products (Immunology)
1 (Oct, 2020)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
4 (FY, 2019)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
9 (Dec, 2020)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
1 (FY, 2020)
Phase II Trials Products (Oncology)
2 (FY, 2019)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
6 (FY, 2020)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
14 (FY, 2019)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
7 (Dec, 2020)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Other)
Phase II Trials Products (Other)
2 (Oct, 2020)
Phase II Trials Products (Other)
1 (FY, 2018)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
3 (Dec, 2020)
Phase II Trials Products (Other)
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
27 (FY, 2019)
Phase III Trials Products
4 (FY, 2019)
Phase III Trials Products
N/A
Phase III Trials Products
14 (Feb, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
14 (FY, 2019)
Phase III Trials Products
44 (Q4, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products (Immunology)
Phase III Trials Products (Immunology)
1 (Oct, 2020)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
4 (FY, 2019)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
7 (Dec, 2020)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
4 (Oct, 2020)
Phase III Trials Products (Oncology)
1 (FY, 2019)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
9 (FY, 2019)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
22 (Q4, 2020)
Phase III Trials Products (Oncology)
26 (Dec, 2020)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Other)
Phase III Trials Products (Other)
1 (Oct, 2020)
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
1 (Dec, 2020)
Phase III Trials Products (Other)
N/A
Products
Products
N/A
Products
24 (FY, 2019)
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Products
1.5 k (FY, 2019)
Products
300 k (FY, 2020)
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
91 (FY, 2019)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
44 (FY, 2016)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Research and Development Centers
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
12 (FY, 2019)
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
29 (FY, 2019)
Research and Development Centers
N/A
Suppliers
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
68 k (FY, 2019)
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
3.5 k (Jun, 2018)
US FDA Breakthrough Therapy Designations
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
6 (FY, 2017)
US FDA Breakthrough Therapy Designations
4 (FY, 2019)
US FDA Breakthrough Therapy Designations
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 30m
Total funding raised
$ 310m
Total funding raised
$ 175.5m
Total funding raised
$ 15.5m
Total funding raised
$ 6.9m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 6.5m
Total funding raised
$ 2.8b
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Gilead Sciences
HQ
Foster City, US
Employees
11,800↑ 7% increase

Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

View company
Immunomedics
HQ
Morris Plains, US
Employees
366↑ 6% increase

Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.

View company
Sanofi
HQ
Paris, FR
Employees
100,409↓ 4% decrease

Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.

View company
Amgen
HQ
Thousand Oaks, US
Employees
23,400↑ 9% increase

Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products.

View company